Utilizing prospective tumor-blood paired sequencing data from 46,906 patients who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) testing, the study found a notable enrichment of CH-positive patients among those with P/LP germline mutations. The gene discussed is C4B; the disease is cancer.